临床研究
肝细胞癌肿瘤坏死的程度后动脉化疗影响患者生存?
|
|
mRECIST类别 |
价值 |
完整的
() |
部分
() |
稳定的
() |
进步
() |
|
| 年龄(平均±标准差) |
61.5±8.7 |
61.5±10.1 |
63.1±9.5 |
61.9±8.3 |
0.697 |
|
| 性别 |
|
|
|
|
|
| 女 |
73例(71.6%) |
110例(79.7%) |
40 (71.4%) |
10 (63.5%) |
0.102 |
| 男性 |
29 (28.4%) |
28 (20.3%) |
23 (28.6%) |
4 (36.5%) |
|
|
| 比赛 |
|
|
|
|
|
| 白色的 |
78例(76.5%) |
105例(76.1%) |
43 (68.3%) |
7 (50.0%) |
0.064 |
| 黑色的 |
18 (17.7%) |
30 (21.7%) |
13 (20.6%) |
6 (42.9%) |
|
| 其他 |
6 (5.8%) |
3 (2.2%) |
7 (11.1%) |
1 (7.1%) |
|
|
| 病因 |
|
|
|
|
|
| 酒精 |
29 (28.4%) |
35 (25.4%) |
13 (21.0%) |
2 (14.3%) |
0.563 |
| 乙型肝炎病毒 |
7 (6.9%) |
6 (4.4%) |
5 (7.9%) |
2 (14.3%) |
0.434 |
| 丙肝病毒 |
57 (55.9%) |
73例(52.9%) |
21 (33.9%) |
5 (35.7%) |
0.024 |
| 纳什 |
22 (21.6%) |
28 (20.3%) |
10 (15.9%) |
1 (7.1%) |
0.402 |
|
| 儿童类 |
|
|
|
|
0.525 |
| 一个 |
35 (34.3%) |
53 (38.4%) |
28 (44.4%) |
7 (50.0%) |
|
| B |
54 (52.9%) |
74例(53.6%) |
28 (44.4%) |
7 (50.0%) |
|
| C |
13 (12.8%) |
11 (8.0%) |
7 (11.2%) |
0 (0.0%) |
|
|
| 法新社 |
12.3±100.8 |
22.0±158.9 |
27.0±132.6 |
132.0±3601.0 |
0.179 |
|
| 直径最大的肿瘤 |
3.6±1.8 |
4.6±2.5 |
5.6±4.4 |
6.1±3.7 |
< 0.0001 |
|
| 数量的肿瘤 |
1.6±0.8 |
1.5±1.0 |
2.1±1.4 |
1.9±1.6 |
0.003 |
|
|
中位数和四分位范围。
克鲁斯卡尔-沃利斯程序使用。
别说话:动脉化疗;在实体肿瘤mRECIST:修改响应评估标准,价值:概率,SD:标准差,乙肝病毒:乙肝病毒、丙肝病毒:纳什:非酒精性脂肪肝炎,丙型肝炎病毒和法新社:α胎蛋白。
|
